<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04426968</url>
  </required_header>
  <id_info>
    <org_study_id>L47-HB-II-02</org_study_id>
    <nct_id>NCT04426968</nct_id>
  </id_info>
  <brief_title>A Phase II Study of Hepalatide in Subjects With HBeAg-positive Chronic Hepatitis B</brief_title>
  <official_title>A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect Relationship Study of Hepalatide for Injection Combined With Pegylated Interferon in Subjects With HBeAg-positive Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai HEP Pharmaceatical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai HEP Pharmaceatical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center, Dose-effect
      Relationship Study of Hepalatide for Injection Combined with Pegylated Interferon in Subjects
      with HBeAg-positive Chronic Hepatitis B
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a 4-arm parallel design, randomized, double-blind, placebo-controlled,
      multicenter, dose-effect relationship, phase II clinical trial. The study is designed to
      assess efficacy and safety of 3 Doses of hepalatide in Combination with Pegylated Interferon
      Compared to Pegylated Interferon Alone in patients with Chronic Hepatitis B .Subjects will be
      randomly assigned to the 2.1mg, 4.2mg, and 6.3mg dose groups , 32 subjects in each group .
      The subjects in each dose group will be randomly and double-blindly administered the
      corresponding dose of trial drug or placebo in a ratio of 3:1. The subjects in each dose
      group who received placebo treatment combine as the placebo group. All subjects will receive
      Pegylated Interferon treatment for 28 weeks as the basic treatment,trial drug or placebo
      treatment for 24 weeks continuously , followed by a safety follow-up for 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>initial virological response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA＜20 IU/ml</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HBV DNA down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA down from baseline log10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Virological suppression</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA &lt;2,000 IU/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>No response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBsAg &gt;20,000 IU/ml and HBV DNA lower than baseline &lt;2log10 IU/ml</description>
  </other_outcome>
  <other_outcome>
    <measure>Partial virological response</measure>
    <time_frame>24weeks</time_frame>
    <description>HBV DNA &gt;20 IU/ml and ≥2log10 IU/ml lower than baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>HBsAg is down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBsAg is down from baseline log10</description>
  </other_outcome>
  <other_outcome>
    <measure>HBeAg turned negative</measure>
    <time_frame>24weeks</time_frame>
    <description>HBeAg &lt;0.05 index</description>
  </other_outcome>
  <other_outcome>
    <measure>HBeAg is down from baseline</measure>
    <time_frame>24weeks</time_frame>
    <description>HBeAg is down from baseline log10</description>
  </other_outcome>
  <other_outcome>
    <measure>ALT recurrence</measure>
    <time_frame>24weeks</time_frame>
    <description>ALT≤1.25×ULN</description>
  </other_outcome>
  <other_outcome>
    <measure>Histological response</measure>
    <time_frame>24weeks</time_frame>
    <description>Liver tissue inflammatory necrosis score reduced by ≥2 points with no increased liver fibrosis score; liver fibrosis score reduced by ≥1 point</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hepatitis B, Chronic</condition>
  <arm_group>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 2.1mg</intervention_name>
    <description>2.1 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 4.2mg</intervention_name>
    <description>4.2mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hepalatide 6.3mg</intervention_name>
    <description>6.3mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 2.1mg</intervention_name>
    <description>2.1 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 4.2mg</intervention_name>
    <description>4.2 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo 6.3mg</intervention_name>
    <description>6.3 mg/day subcutaneously (s.c.) for 24 week</description>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon</intervention_name>
    <description>180 ug/week subcutaneously (s.c.) for 28 week</description>
    <arm_group_label>Hepalatide 2.1mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>Hepalatide 4.2mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>Hepalatide 6.3mg+Pegylated Interferon</arm_group_label>
    <arm_group_label>placebo+Pegylated Interferon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age from 18 to 60 years inclusively at the time of signing Informed Consent Form.

          2. HBsAg or/and HBV DNA Positive for at least 6 months before Screening.

          3. Subjects did not receive interferon treatment and did not receive
             nucleotide/nucleoside analogue within 6 months

          4. HBeAg positive

          5. HBV DNA≥20,000 IU/ml

          6. 2×ULN ≤ALT≤10×ULN

          7. Serum total bilirubin＜2×ULN

          8. Subjects had no history of decompensated liver disease（Ascites, jaundice, hepatic
             encephalopathy, varicose hemorrhage）, serious heart disease (including unstable or
             uncontrolled heart disease within 6 months),serious mental illness (especially
             depression),organ transplantation .subjects have no uncontrolled epilepsy, mental
             illness, diabetes and hypertension,no autoimmune disease, immune related extrahepatic
             manifestations (vasculitis, purpura, nodular arteritis, peripheral neuropathy and
             glomerulonephritis), thyroid disease, malignant tumor, immunosuppressive therapy; no
             basic diseases and other serious diseases such as serious infection, retinal disease,
             heart failure and chronic obstructive pulmonary disease; no alcohol and drug abuse.

          9. Subjects must agree to use a highly effective contraception for 2 years , female
             subjects are not pregnant or breastfeeding

         10. Subjects did not donate blood or as clinical trial subjects within 3 months before
             screening

         11. Subjects have good compliance with the protocol

         12. Subjects understood and agreed to sign the informed consent form.

        Exclusion Criteria:

          1. Decompensated liver disease: direct bilirubin &gt; 1.2 × ULN, prothrombin time &gt; 1.2 ×
             ULN, serum albumin &lt; 35 g / L

          2. Hemocytopenia: neutrophil &lt; 1 × 10^9 / L, platelet &lt; 50 × 10^9 / L, hemoglobin &lt; 100g
             / L (female) or hemoglobin &lt; 110g / L (male)

          3. Severe liver fibrosis or cirrhosis: METAVIR score of liver biopsy is 4 points; or LSM
             score of FibroScan ≥ 12.17 kPa

          4. HAV,HCV,HDV,HEV or HIV infection

          5. Allergic to interferon

          6. Positive for anti-HBV Pre-S1 antibody.

          7. Hamilton Depression Scale (HAMD, 17 items) score &gt; 17 points

          8. Child-Pugh score＞ 6 points

          9. Female subjects pregnancy test positive

         10. Other laboratories or auxiliary examinations are obviously abnormal
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fusheng Wang</last_name>
    <role>Principal Investigator</role>
    <affiliation>The fifth medical center of PLA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hongli Liu</last_name>
    <phone>86-21-68412368</phone>
    <phone_ext>605</phone_ext>
    <email>liuhongli_hep@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fei Cai</last_name>
    <phone>86-21-68412368</phone>
    <phone_ext>620</phone_ext>
    <email>caifei_hep@163.com</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>June 9, 2020</last_update_submitted>
  <last_update_submitted_qc>June 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

